Common antidepressant drugs linked to lactation difficulties in moms

Jan 26, 2010

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), women taking commonly used forms of antidepressant drugs may experience delayed lactation after giving birth and may need additional support to achieve their breastfeeding goals.

Breastfeeding benefits both infants and mothers in many ways as breast milk is easy to digest and contains antibodies that can protect infants from bacterial and viral infections. The World Health Organization recommends that infants should be exclusively breastfed for the first six months of life. This new study shows that certain common antidepressant drugs may be linked to a common difficulty experienced by new mothers known as delayed secretory activation, defined as a delay in the initiation of full milk secretion.

"The breasts are serotonin-regulated glands, meaning the breasts' ability to secrete milk at the right time is closely related to the body's production and regulation of the hormone serotonin," said Nelson Horseman, PhD, of the University of Cincinnati and co-author of the study. "Common like fluoxetine, sertraline and paroxetine are known as selective serotonin reuptake inhibitor (SSRI) drugs and while they can affect mood, emotion and sleep they may also impact serotonin regulation in the breast, placing new mothers at greater risk of a delay in the establishment of a full milk supply."

In this study, researchers examined the effects of SSRI drugs on lactation using laboratory studies of human and animal cell lines and genetically modified mice. Furthermore, an observational study evaluated the impact of SSRI drugs on the onset of milk production in postpartum women. In this study of 431 postpartum women, median onset of lactation was
85.8 hours postpartum for the SSRI-treated mothers and 69.1 hours for mothers not treated with SSRI drugs. Researchers commonly define delayed secretory activation as occurring later than 72 hours postpartum.

"SSRI drugs are very helpful medications for many moms, so understanding and ameliorating difficulties moms experience can help them achieve their goals for breastfeeding their babies," said Horseman. "More human research is needed before we can make specific recommendations regarding SSRI use during breastfeeding."

Explore further: FDA approves new drug for rare genetic disease

More information: The article, "Serotonin transport and metabolism in the mammary gland modulates secretory activation and involution," will appear in the February 2010 issue of JCEM.

add to favorites email to friend print save as pdf

Related Stories

Treating SSRI-resistant depression

Mar 25, 2008

When your antidepressant medication does not work, should you switch to a different medication from the same class or should you try an antidepressant medication that has a different mechanism of action" This is the question ...

Link Between Antidepressants and Birth Defect

Sep 29, 2009

(PhysOrg.com) -- Researchers in Denmark have studied almost half a million Danish children and found a slightly higher rate of septal heart abnormalities in babies whose mothers took an SSRI antidepressant ...

Serotonin Made in Breast Cancer Cells, Researchers Show

Nov 24, 2009

(PhysOrg.com) -- Researchers at the University of Cincinnati have documented that the brain hormone serotonin is made in human breast cancer cells and functions abnormally, contributing to malignant growth.

Codeine not safe for all breastfeeding moms and their babies

Aug 20, 2008

Using pain treatments which contain codeine may be risky for some breastfeeding mothers, according to researchers at The University of Western Ontario, and the Hospital for Sick Children (SickKids) in Toronto. Lead author ...

Recommended for you

Boxed warnings are common in novel therapeutics

20 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

21 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

22 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0